澳洲麦觉理大学论文代写：葛兰素史克
考虑不同部分分别减少销售药品和营养产品被报道为1.1%。强生的皮肤护理产品销售下降了2.6%,葛兰素史克的增加了5.8%。有一个婴儿护理产品的销售下降3.7%。没有改变口腔护理产品的销售负责强生公司和口腔护理葛兰素史克公司的销售增加了0.7%。下降9.3%的女性护理产品强生被观察到。消费总额是强生的减少了2.9%,另一方面有一个在葛兰素史克公司增长了3.7%。
总体上可以说,葛兰素史克的性能比强生(Johnson & Johnson)要好得多。所有业务部门的分析显示,葛兰素史克公司的盈利能力相对比,强生的类似的片段。强生公司的盈利能力恶化背后的主要原因是它所面临的条件在美国国内。在美国的销量下降主要是由于低销售的止痛剂由于供给约束和营养产品的竞争压力。上呼吸道的强劲增长,消化健康和止痛剂产品在美国以外抵消了消极的货币。可以得出的结论是,两家公司的商业趋势正在改变和相当大的变化在两个(在跨国制药公司)的排名可以预期。
澳洲麦觉理大学论文代写：葛兰素史克
Considering different segments separately a decrease in sale of pharmaceutical and nutritional products was reported to be 1.1%. Skin care products sale of J&J was decreased by 2.6% and that of GlaxoSmithKline were increased by 5.8%. There was a 3.7% decline in baby care product’s sales. There was no change in oral care product’s sales for J&J and a 0.7% increase in oral care sales of GlaxoSmithKline. A decline of 9.3% in women’s care products of J&J was observed. Total consumer sales were reduced by 2.9% of J&J, on the other hand there was an increase of 3.7% in case of GlaxoSmithKline.
On the whole it can be said that performance of GlaxoSmithKline is much better than Johnson & Johnson. Analysis of all business segments reveals that profitability of GlaxoSmithKline is relatively better than that of similar segments of J&J. The major reason behind deteriorated profitability of J&J is the condition it faces in United States which is its home country. Sales in the U.S. decreased primarily due to lower sales of analgesics as a result of supply constraints and competitive pressures in nutritional products. Strong growth of upper respiratory, digestive health and analgesics products outside the U.S. was offset by negative currency. It can be concluded that the business trends are changing in the two companies and a considerable change in the ranking of two (among multinational pharmaceutical companies) can be expected.
